Los Angeles - Cutaneous atrophy, the bane of topical corticosteroid treatment, may have met its match in a thyroid hormone analogue, according to Jan Faergemann, M.D., Ph.D.
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation